We use cookies on our website. Carry on browsing if you’re happy with this or find out more
Featured article: Forbes on Kymab: exciting the big guys
Forbes magazine recognises Kymab's work is 'exciting the big and little guys' and places the company in a select group of UK 'Unicorns'
Read article
Featured article: Promising First Clinical Study of KY1005 for immune-mediated diseases
Positive data in Phase I trial of KY1005 will lead to Phase II studies in atopic dermatitis, with additional plans to run studies in othe...
Read article